Health Condition 1: D899- Disorder involving the immune mechanism, unspecified
Conditions
Interventions
Control Intervention1: NIL: NIL
Sponsors
Datta Meghe Institute of Higher Education and Research
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with sepsis: Only individuals who meet the clinical criteria for sepsis (e.g., infection with systemic inflammatory response) should be included in the study. 2.Adults aged 18 years and above: Include adult patients, as the study may focus on how glucose and lymphocyte ratios impact prognosis in the adult population. 3.Availability of relevant laboratory data: Participants should have recent blood tests, including glucose levels and lymphocyte counts, available for analysis to calculate the glucose and lymphocyte ratio.
Exclusion criteria
Exclusion criteria: 1.Diabetic patients Pre-existing diabetes alters glucose levels affecting study outcomes. 2.Immunosuppressed patients Those on chemotherapy, steroids, or immunosuppressants may have skewed lymphocyte ratios. 3.Hematologic or autoimmune disorders Conditions like leukemia or lupus impact lymphocyte counts introducing bias.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Mortality rate 28-day in-hospital mortality. 2.ICU length of stay Duration of ICU admission. 3.Organ dysfunction progression Evaluated using SOFA score changes.Timepoint: 1.Mortality rate 28-day in-hospital mortality. 2.ICU length of stay Duration of ICU admission. 3.Organ dysfunction progression Evaluated using SOFA score changes. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Need for mechanical ventilation Incidence and duration of ventilatory support. 2.Vasopressor requirement Need and duration of vasopressor therapy. 3.Septic shock development Progression from sepsis to septic shock. 4.Hospital length of stay Total duration of hospitalization. 5.Inflammatory markers Trends in CRP and procalcitonin levels.Timepoint: 1.At admission (Day 0) Baseline assessment. 2.Day 3 & Day 7 Follow-up evaluation of progression. 3.Day 14 Intermediate outcome assessment. 4.Day 28 Final outcome evaluation. | — |
Countries
India
Contacts
Public ContactDr Jaswanth Varma Alluri
Datta Meghe Institute of Higher education and Research
Outcome results
None listed